Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04309084
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:18.735634+00:00
Published At
2023-02-16T00:00:00+00:00
Record Updated At
2023-02-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Multiple Myeloma", "Neoplasm, Plasma Cell", "Neoplasms by Histologic Type", "Neoplasms", "Hemostatic Disorder", "Vascular Diseases", "Cardiovascular Diseases", "Paraproteinemias", "Blood Protein Disorders", "Hematologic Diseases", "Hemorrhagic Disorders", "Lymphoproliferative Disorders", "Immunoproliferative Disorders", "Immune System Diseases", "Antineoplastic Agents", "Analgesics, Non-Narcotic", "Analgesics", "Sensory System Agents", "Peripheral Nervous System Agents", "Physiological Effects of Drugs"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-02-16"
protocolSection.identificationModule.nctId
"NCT04309084"
protocolSection.identificationModule.officialTitle
"A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting."
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Neoplasm, Plasma Cell (protocolSection.conditionsModule.conditions)
  • Neoplasms by Histologic Type (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Hemostatic Disorder (protocolSection.conditionsModule.conditions)
  • Vascular Diseases (protocolSection.conditionsModule.conditions)
  • Cardiovascular Diseases (protocolSection.conditionsModule.conditions)
  • Paraproteinemias (protocolSection.conditionsModule.conditions)
  • Blood Protein Disorders (protocolSection.conditionsModule.conditions)
  • Hematologic Diseases (protocolSection.conditionsModule.conditions)
  • Hemorrhagic Disorders (protocolSection.conditionsModule.conditions)
  • Lymphoproliferative Disorders (protocolSection.conditionsModule.conditions)
  • Immunoproliferative Disorders (protocolSection.conditionsModule.conditions)
  • Immune System Diseases (protocolSection.conditionsModule.conditions)
  • Antineoplastic Agents (protocolSection.conditionsModule.conditions)
  • Analgesics, Non-Narcotic (protocolSection.conditionsModule.conditions)
  • Analgesics (protocolSection.conditionsModule.conditions)
  • Sensory System Agents (protocolSection.conditionsModule.conditions)
  • Peripheral Nervous System Agents (protocolSection.conditionsModule.conditions)
  • Physiological Effects of Drugs (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.